Since activation of NF-κB leads to inflammation that in turn is involved in the pathogenesis of many diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease [6], much attention has focused on the development of anti-inflammatory drugs targeting NF-κB [7]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.